Anteris Technologies Ltd
Anteris Technologies Ltd (ASX:AVR) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.
Related news
- Anteris Technologies’ 3D single-piece aortic valve DurAVR™ a ‘Best Innovation’ at PCR London Valves 2020
2020-11-23 - Admedus successfully implants second patient in SAVR trial
2020-05-11 - Admedus receives approval to sell CardioCel 3D® in Israel
2019-09-05 - Admedus从星光控股的进一步收购中获得了$340.25万元的资金
2018-09-06 - Admedus receives $3.425 million in funds from further Star Bright placement
2018-09-06 - Admedus receives $3.425 million in funds from further Star Bright placement
2018-09-06 - Admedus secures strategic cornerstone investor from Hong Kong
2018-09-03 - Admedus progressing to animal trials of its unique heart valve device
2018-05-22 - Admedus takes significant step forward in developing unique heart valve device
2018-04-19 - Admedus secures regulatory approval in Canada for heart tissue products
2018-03-07 - Admedus receives approval to sell CardioCel in India
2017-11-23 - Admedus eyes new revenue stream through supply agreement with 4C Medical Technologies
2017-09-01 - Admedus shares open higher on FDA clearance for CardioCel 3D
2017-05-02 - Admedus reports strong sales growth in December half
2017-02-27 - Admedus Ltd receives some more positive results from HSV-2 study
2016-10-19 - Admedus Ltd finishes off $18.3M raising to fund growth
2016-09-01 - Admedus Ltd grows FY16 sales by 40% as future forecasts accelerate
2016-07-20 - Admedus Ltd: New York's Maxim Group maintains A$2.00 price target
2016-07-13 - Admedus Ltd awarded major supply contract with Royal Adelaide Hospital
2016-05-25 - Admedus Ltd wins the peer voted ‘Manufacturer of the Year’ award
2016-05-13 - Admedus Ltd to showcase CardioCel® in the U.S. to drive sales
2016-05-12 - Admedus Ltd posts 73% increase in March quarter sales
2016-04-29 - Admedus Ltd expands distribution agreement with CORONEO
2016-04-08 - Admedus Ltd demonstrates close profile to native aortic valve
2016-03-29 - Admedus Ltd receives $2.00 price target from New York based Maxim Group
2016-03-14 - Admedus Ltd receives A$1.95 valuation from Hong Kong firm
2016-03-10 - Admedus has encouraging results from Phase II herpes simplex trial
2016-03-04 - Admedus delivers strong revenue growth on CardioCel® roll-out
2016-02-26 - Admedus to add revenue as heart disease tech distribution grows
2016-01-27 - Admedus finishes 2015 in strong position after achieving milestones
2015-12-24 - Admedus attracts U.S. investors in private placement
2015-12-22 - Admedus pumping along: broker report
2015-11-13 - Admedus taps huge European market with green light for CardioCel
2015-11-09 - Admedus to add revenue as global CardioCel rollout enters Malaysia
2015-11-04 - Admedus Limited underlines viability of expanding heart surgery method
2015-10-06 - Admedus and Ear Science Institute Australia team up on stem cell delivery
2015-09-30 - Admedus starts heart valve clinical study
2015-09-23 - Admedus rapid revenue growth driven by global sales success
2015-07-30 - Admedus’ CardioCel has long term potential for congenital heart disease
2015-07-08 - Admedus' CardioCel cardiovascular used in 80 treatment centres
2015-06-18 - Admedus moves to second dose of Herpes vaccine
2015-06-05 - Admedus Limited launches new CardioCel product for vascular repair
2015-05-18 - Admedus appoints Genpharm as Middle East, North Africa distributor
2015-04-22 - Admedus receives A$0.20 price target from Morgans
2015-04-21 - Admedus Limited with $28M funding to grow global healthcare business
2015-04-17 - Admedus has high hopes for Herpes vaccine as dosing commences
2015-04-10 - Admedus Limited expands market for ADAPT® tissue products
2015-04-07 - Admedus clinches $12M in oversubscribed placement
2015-03-18 - Admedus expands CardioCel® market, anticipates record sales
2015-03-12 - Admedus receives A$0.22 price target from Morgans
2015-03-03 - Admedus: CardioCel® sales growth drives revenue higher
2015-02-02 - Admedus on track to becoming an integrated healthcare company
2014-12-03 - Admedus finds success in Human Papilloma Virus vaccine studies
2014-11-24 - Admedus CardioCel® gains approval in Singapore
2014-11-03 - Admedus Limited to launch CardioCel® medical device in Canada
2014-10-20 - Admedus vaccine for herpes has success; moves to next clinical trial
2014-10-02 - Admedus delivers more stellar results
2014-07-30 - Admedus increases interest in Prof Ian Frazer’s vaccines
2014-07-24 - Admedus expects $9M income for financial year
2014-06-26
